The role of umbilical cord serum therapy on corneal epithelial defect

The role of umbilical cord serum therapy on improvement of corneal epithelial defect following diabetic vitrectomy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138903241180N15

Enrollment

Registered

2010-06-14

Start date

2009-12-28

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

corneal epithelial defect. Disorder of cornea, unspecified

Interventions

Intervention 1: Intervention: chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours. Interven

Treatment - Drugs

Intervention: chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours

Control: chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Diabetic patients with corneal epithelial defect following diabetic vitrectomy at labbafinejad hospital. Exclusion criteria: 1) Any history of Eye herpes infection, Refractive surgery, Autoimmune disease, Immune defficiency; 2) patients with one eye 3) use of any eye drops except Chloramphenicol, Betamethasone, Cycloplegic and contact lens for corneal epithelial defect.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Measurement of corneal epithelial defect. Timepoint: days 3,5,7,12. Method of measurement: slit lamp.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Amir Faramarzi

Ophthalmic Rsearch Center

labbafi@hotmail.com+98 21 2259 2200

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026